QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
QQQ   304.10 (-1.64%)
AAPL   120.13 (-1.58%)
MSFT   226.73 (-0.36%)
FB   257.64 (+0.87%)
GOOGL   2,033.93 (+1.12%)
TSLA   621.44 (-4.86%)
AMZN   2,977.57 (-0.91%)
NVDA   494.81 (-3.39%)
BABA   230.50 (-2.44%)
CGC   31.01 (-6.71%)
GE   13.57 (+0.97%)
MU   84.33 (-5.36%)
NIO   39.28 (-5.42%)
AMD   77.75 (-3.85%)
T   28.92 (+0.70%)
F   11.93 (-1.97%)
ACB   9.82 (-6.12%)
DIS   188.03 (-2.20%)
BA   224.71 (-1.68%)
NFLX   511.29 (-1.81%)
BAC   36.50 (+0.72%)
Log in
NASDAQ:OBSV

ObsEva Competitors

$3.37
-0.31 (-8.42 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.21
Now: $3.37
$3.74
50-Day Range
$2.11
MA: $3.96
$5.05
52-Week Range
$1.63
Now: $3.37
$6.30
Volume3.17 million shs
Average Volume8.47 million shs
Market Capitalization$161.76 million
P/E RatioN/A
Dividend YieldN/A
Beta0.99

Competitors

ObsEva (NASDAQ:OBSV) Vs. AKUS, BCEL, ICPT, MGTA, RIGL, and ARDX

Should you be buying OBSV stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to ObsEva, including Akouos (AKUS), Atreca (BCEL), Intercept Pharmaceuticals (ICPT), Magenta Therapeutics (MGTA), Rigel Pharmaceuticals (RIGL), and Ardelyx (ARDX).

Akouos (NASDAQ:AKUS) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent recommendations for Akouos and ObsEva, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Akouos00403.00
ObsEva11302.40

Akouos presently has a consensus price target of $33.00, indicating a potential upside of 76.00%. ObsEva has a consensus price target of $11.80, indicating a potential upside of 250.15%. Given ObsEva's higher probable upside, analysts plainly believe ObsEva is more favorable than Akouos.

Insider and Institutional Ownership

88.7% of Akouos shares are held by institutional investors. Comparatively, 52.7% of ObsEva shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Akouos and ObsEva's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AkouosN/AN/AN/AN/AN/A
ObsEvaN/AN/A$-108,790,000.00($2.49)-1.35

Profitability

This table compares Akouos and ObsEva's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AkouosN/AN/AN/A
ObsEvaN/A-256.23%-93.21%

Summary

Akouos beats ObsEva on 5 of the 6 factors compared between the two stocks.

ObsEva (NASDAQ:OBSV) and Atreca (NASDAQ:BCEL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Analyst Ratings

This is a summary of recent ratings and recommmendations for ObsEva and Atreca, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ObsEva11302.40
Atreca00603.00

ObsEva presently has a consensus price target of $11.80, indicating a potential upside of 250.15%. Atreca has a consensus price target of $29.00, indicating a potential upside of 66.48%. Given ObsEva's higher possible upside, research analysts clearly believe ObsEva is more favorable than Atreca.

Volatility and Risk

ObsEva has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500. Comparatively, Atreca has a beta of 0.08, meaning that its stock price is 92% less volatile than the S&P 500.

Earnings & Valuation

This table compares ObsEva and Atreca's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ObsEvaN/AN/A$-108,790,000.00($2.49)-1.35
AtrecaN/AN/A$-67,480,000.00($4.26)-4.09

Atreca is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

52.7% of ObsEva shares are owned by institutional investors. Comparatively, 69.6% of Atreca shares are owned by institutional investors. 9.9% of Atreca shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares ObsEva and Atreca's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ObsEvaN/A-256.23%-93.21%
AtrecaN/A-43.21%-40.98%

Summary

Atreca beats ObsEva on 7 of the 11 factors compared between the two stocks.

Intercept Pharmaceuticals (NASDAQ:ICPT) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk and earnings.

Profitability

This table compares Intercept Pharmaceuticals and ObsEva's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intercept Pharmaceuticals-106.64%-1,973.10%-48.51%
ObsEvaN/A-256.23%-93.21%

Institutional and Insider Ownership

85.8% of Intercept Pharmaceuticals shares are held by institutional investors. Comparatively, 52.7% of ObsEva shares are held by institutional investors. 23.7% of Intercept Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Intercept Pharmaceuticals and ObsEva's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intercept Pharmaceuticals$252 million2.53$-344,680,000.00($10.89)-1.78
ObsEvaN/AN/A$-108,790,000.00($2.49)-1.35

ObsEva has lower revenue, but higher earnings than Intercept Pharmaceuticals. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Intercept Pharmaceuticals and ObsEva, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intercept Pharmaceuticals214802.25
ObsEva11302.40

Intercept Pharmaceuticals presently has a consensus target price of $50.8696, suggesting a potential upside of 163.16%. ObsEva has a consensus target price of $11.80, suggesting a potential upside of 250.15%. Given ObsEva's stronger consensus rating and higher probable upside, analysts clearly believe ObsEva is more favorable than Intercept Pharmaceuticals.

Volatility and Risk

Intercept Pharmaceuticals has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500. Comparatively, ObsEva has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500.

Summary

ObsEva beats Intercept Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Magenta Therapeutics (NASDAQ:MGTA) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Profitability

This table compares Magenta Therapeutics and ObsEva's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Magenta TherapeuticsN/A-53.42%-47.67%
ObsEvaN/A-256.23%-93.21%

Valuation and Earnings

This table compares Magenta Therapeutics and ObsEva's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Magenta TherapeuticsN/AN/A$-76,770,000.00($2.07)-6.33
ObsEvaN/AN/A$-108,790,000.00($2.49)-1.35

Magenta Therapeutics is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Magenta Therapeutics has a beta of 2.46, meaning that its share price is 146% more volatile than the S&P 500. Comparatively, ObsEva has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500.

Institutional and Insider Ownership

59.3% of Magenta Therapeutics shares are held by institutional investors. Comparatively, 52.7% of ObsEva shares are held by institutional investors. 10.9% of Magenta Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for Magenta Therapeutics and ObsEva, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Magenta Therapeutics00403.00
ObsEva11302.40

Magenta Therapeutics presently has a consensus target price of $17.6667, suggesting a potential upside of 34.86%. ObsEva has a consensus target price of $11.80, suggesting a potential upside of 250.15%. Given ObsEva's higher probable upside, analysts clearly believe ObsEva is more favorable than Magenta Therapeutics.

Summary

Magenta Therapeutics beats ObsEva on 9 of the 11 factors compared between the two stocks.

ObsEva (NASDAQ:OBSV) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Profitability

This table compares ObsEva and Rigel Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ObsEvaN/A-256.23%-93.21%
Rigel Pharmaceuticals-26.25%-44.96%-20.08%

Insider & Institutional Ownership

52.7% of ObsEva shares are owned by institutional investors. Comparatively, 82.0% of Rigel Pharmaceuticals shares are owned by institutional investors. 4.7% of Rigel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

ObsEva has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500.

Earnings & Valuation

This table compares ObsEva and Rigel Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ObsEvaN/AN/A$-108,790,000.00($2.49)-1.35
Rigel Pharmaceuticals$59.29 million10.20$-66,890,000.00($0.40)-8.95

Rigel Pharmaceuticals has higher revenue and earnings than ObsEva. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for ObsEva and Rigel Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ObsEva11302.40
Rigel Pharmaceuticals01302.75

ObsEva presently has a consensus target price of $11.80, indicating a potential upside of 250.15%. Rigel Pharmaceuticals has a consensus target price of $8.3333, indicating a potential upside of 132.77%. Given ObsEva's higher possible upside, equities research analysts plainly believe ObsEva is more favorable than Rigel Pharmaceuticals.

Summary

Rigel Pharmaceuticals beats ObsEva on 9 of the 12 factors compared between the two stocks.

Ardelyx (NASDAQ:ARDX) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

Valuation and Earnings

This table compares Ardelyx and ObsEva's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ardelyx$5.28 million113.84$-94,940,000.00($1.47)-4.53
ObsEvaN/AN/A$-108,790,000.00($2.49)-1.35

Ardelyx has higher revenue and earnings than ObsEva. Ardelyx is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ardelyx and ObsEva's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ardelyx-1,063.74%-53.93%-37.42%
ObsEvaN/A-256.23%-93.21%

Volatility & Risk

Ardelyx has a beta of 2.02, indicating that its stock price is 102% more volatile than the S&P 500. Comparatively, ObsEva has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Ardelyx and ObsEva, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ardelyx00303.00
ObsEva11302.40

Ardelyx presently has a consensus price target of $14.00, indicating a potential upside of 110.21%. ObsEva has a consensus price target of $11.80, indicating a potential upside of 250.15%. Given ObsEva's higher possible upside, analysts plainly believe ObsEva is more favorable than Ardelyx.

Insider and Institutional Ownership

85.9% of Ardelyx shares are owned by institutional investors. Comparatively, 52.7% of ObsEva shares are owned by institutional investors. 4.0% of Ardelyx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Ardelyx beats ObsEva on 9 of the 12 factors compared between the two stocks.


ObsEva Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Akouos logo
AKUS
Akouos
1.7$18.75-11.0%$644.68 millionN/A0.00High Trading Volume
BCEL
Atreca
1.7$17.42-4.2%$639.44 millionN/A-6.18Earnings Announcement
Analyst Revision
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.9$19.33-7.3%$638.20 million$252 million-1.98Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$13.10-0.6%$632.80 millionN/A-6.72Earnings Announcement
High Trading Volume
News Coverage
Gap Up
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.58-7.0%$604.95 million$59.29 million-23.87Earnings Announcement
Analyst Revision
News Coverage
Ardelyx logo
ARDX
Ardelyx
1.9$6.66-3.0%$601.05 million$5.28 million-6.59Upcoming Earnings
IVA
Inventiva
0.0$14.61-2.6%$592.79 millionN/A0.00News Coverage
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.66-1.9%$591.64 million$143.01 million-1.08
Chimerix logo
CMRX
Chimerix
1.3$9.17-12.1%$574.35 million$12.52 million-16.09Earnings Announcement
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$31.56-2.0%$566.25 million$12.69 million-15.17Upcoming Earnings
Flexion Therapeutics logo
FLXN
Flexion Therapeutics
1.4$11.47-1.7%$565.64 million$72.96 million-3.71Upcoming Earnings
News Coverage
Geron logo
GERN
Geron
1.4$1.77-4.0%$549.54 million$460,000.00-5.06Upcoming Earnings
IDYA
IDEAYA Biosciences
1.3$18.83-7.5%$547.39 millionN/A-10.02
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.7$41.81-3.6%$544.78 million$195.89 million119.46Earnings Announcement
News Coverage
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$33.22-1.8%$539.56 millionN/A-15.38
IVERIC bio logo
ISEE
IVERIC bio
1.5$6.00-7.2%$537.41 millionN/A-4.76Earnings Announcement
News Coverage
XBiotech logo
XBIT
XBiotech
1.3$18.11-3.8%$529.92 millionN/A1.26
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.18-0.0%$529.78 millionN/A-3.14News Coverage
Foghorn Therapeutics logo
FHTX
Foghorn Therapeutics
1.5$14.69-11.0%$526.11 millionN/A0.00Upcoming Earnings
AC Immune logo
ACIU
AC Immune
1.3$7.33-0.0%$525.86 million$111.75 million-8.14
Molecular Templates logo
MTEM
Molecular Templates
2.0$10.43-4.0%$521.13 million$22.27 million-5.11Upcoming Earnings
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.6$3.32-1.5%$509.63 million$335 million-1.12Analyst Revision
SIGA
SIGA Technologies
0.3$6.55-0.2%$506.97 million$26.74 million16.38News Coverage
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$13.96-3.5%$499.21 million$58.12 million-16.23Increase in Short Interest
News Coverage
Altimmune logo
ALT
Altimmune
1.9$13.18-9.0%$489.64 million$5.80 million-6.62Analyst Upgrade
Analyst Revision
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$15.90-3.4%$486.45 millionN/A-4.58Upcoming Earnings
Viking Therapeutics logo
VKTX
Viking Therapeutics
1.6$6.55-4.1%$485.57 millionN/A-13.37
BeyondSpring logo
BYSI
BeyondSpring
1.2$12.37-3.8%$484.19 millionN/A-6.06
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$11.43-2.4%$479.32 million$25 million-17.58Upcoming Earnings
News Coverage
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$22.40-7.1%$477.23 million$13.80 million-10.82Upcoming Earnings
News Coverage
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.4$14.45-7.5%$475.72 million$1.19 million-6.02Upcoming Earnings
Summit Therapeutics logo
SMMT
Summit Therapeutics
0.6$5.71-4.4%$471.50 million$56.50 million0.00Decrease in Short Interest
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.20-2.5%$466.95 million$109.33 million-2.35
Inozyme Pharma logo
INZY
Inozyme Pharma
1.7$19.78-2.6%$462.32 millionN/A0.00Increase in Short Interest
News Coverage
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$9.71-9.0%$460.93 millionN/A-3.90Upcoming Earnings
News Coverage
Wave Life Sciences logo
WVE
Wave Life Sciences
1.8$9.34-9.6%$455.59 million$15.98 million-1.65Unusual Options Activity
News Coverage
Gap Up
Affimed logo
AFMD
Affimed
1.6$5.13-9.2%$453.11 million$23.96 million-8.69
Applied Therapeutics logo
APLT
Applied Therapeutics
1.8$17.60-7.5%$448.69 millionN/A-3.70
Syros Pharmaceuticals logo
SYRS
Syros Pharmaceuticals
1.3$7.96-4.5%$447.33 million$1.98 million-4.80News Coverage
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.5$7.56-2.2%$440.54 million$59.22 million37.80Upcoming Earnings
Unusual Options Activity
Homology Medicines logo
FIXX
Homology Medicines
1.6$9.73-7.4%$440.42 million$1.67 million-3.56Upcoming Earnings
Analyst Report
News Coverage
89bio logo
ETNB
89bio
1.6$22.15-10.8%$440.32 millionN/A-4.39News Coverage
Spero Therapeutics logo
SPRO
Spero Therapeutics
1.5$16.10-7.6%$437.71 million$18.15 million-3.79News Coverage
Kala Pharmaceuticals logo
KALA
Kala Pharmaceuticals
1.7$7.09-6.5%$436.40 million$6.07 million-3.39Earnings Announcement
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.8$11.17-6.6%$433.62 millionN/A-8.66Upcoming Earnings
Orphazyme A/S logo
ORPH
Orphazyme A/S
1.3$12.44-4.1%$431.26 millionN/A0.00Analyst Upgrade
Increase in Short Interest
News Coverage
Puma Biotechnology logo
PBYI
Puma Biotechnology
1.4$10.70-3.5%$425.45 million$272.30 million-7.48News Coverage
Spruce Biosciences logo
SPRB
Spruce Biosciences
1.5$18.14-6.3%$421.10 millionN/A0.00Upcoming Earnings
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.9$16.29-9.9%$418.93 millionN/A-4.74Upcoming Earnings
Athenex logo
ATNX
Athenex
1.6$4.48-7.6%$418.68 million$101.23 million-3.07Earnings Announcement
Analyst Report
High Trading Volume
Unusual Options Activity
Analyst Revision
News Coverage
This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.